FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its ...

A CGP assay that detects more than 700 cancer-relevant gene variants and molecular signatures, gives researchers new insights into tumour biology, expanding the potential for personalized cancer ...

Precision medicines and personalized treatments are revolutionizing cancer therapy. Small molecules, biological agents, antibody-drug conjugates and cell-based therapies directed against specific ...

We performed a single-institution, retrospective analysis of CGP utilization and treatment patterns in patients with localized PDAC who underwent curative-intent resection in the contemporary period ...

Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort Compared with rectal AD (n = 1,915), anal AD (n = 45) exhibits higher frequencies of ...

CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...

Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic ...

CNW/ - Pancreatic Cancer North America (PCNA) is launching a new national pilot that will provide pancreatic cancer patients ...

Summit™ 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...

A new national pilot program will provide pancreatic cancer patients across Canada with free access to advanced genomic ...